A global subsidy: Key to affordable drugs for malaria?

Health Affairs

Volumn 28, Issue 4, 2009, Pages 949-961

  Laxminarayan, Ramanan ^a   Gelband, Hellen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISIN DERIVATIVE; CHLOROQUINE; FANSIDAR;

DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG RESEARCH; ENDEMIC DISEASE; HEALTH CARE FINANCING; HUMAN; MALARIA; MEDICAL CARE; MEDICAL INFORMATION; PRACTICE GUIDELINE; REVIEW; UGANDA; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; CHLOROQUINE; DRUG COSTS; DRUG RESISTANCE; FINANCING, ORGANIZED; HEALTH SERVICES ACCESSIBILITY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALARIA; POLITICS;

EID: 67651207370     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.4.949     Document Type: Review

References (29)

1. N. White et al., "Averting a Malaria Disaster," Lancet 353, no. 9168 (1999): 1965-1967.
2. Dalberg Global Development Advisors, Affordable Medicines Facility-Malaria: Technical Design (Geneva: Roll Back Malaria Partnership, 2006). This was difficult to document at the time, although it was something widely held to be true. Subsequent data collection, some in relation to the global subsidy itself, has confirmed that this is, in fact, the case.
3. World Health Organization, Antimalarial Drug Combination Therapy: Report of a Technical Consultation (Geneva: WHO, 2001).
4. IOM committees often take the prerogative to shape the questions presented to them so that they address the specific questions asked, but also cover related policy-relevant questions.
5. J. Bohannon, "Arata Kochi Profile: Fighting Words from WHO's New Malaria Chief," Science 311, no. 5761 (2006): 599.
6. K.J. Arrow, C.B. Panosian, and H. Gelband, Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance (Washington: National Academies Press, 2004).
7. Olusoji Adeyi, World Bank, personal communication to Ramanan Laxminarayan, 2004.
8. R. Laxminarayan, M. Over, and D.L. Smith, Will a Global Subsidy of New Antimalarials Delay the Emergence of Resistance and Save Lives?(Washington: World Bank, 2005);
9. and R. Laxminarayan, M. Over, and D.L. Smith, "Will a Global Subsidy of New Antimalarials Delay the Emergence of Resistance and Save Lives?" Health Affairs 25, no. 2 (2006): 325-336.
10. M. Enserink, "Combating Malaria: Malaria Treatment: Act Two," Science 318, no. 5850 (2007): 560-563;
11. and J. Tanne, "News Roundup: Subsidies for Malaria Treatment Could Save 25,000 Lives a Month," BMJ 332, no. 7541 (2006): 569.
12. Medicines for Malaria Venture, Understanding the Antimalarials Market: Uganda 2007 - An Overview of the Supply Side (Geneva: MMV, 2008);
13. and WHO, World Malaria Report 2008 (Geneva: WHO, 2008).
14. RBM Partnership, The African Summit on Roll Back Malaria, Summary Report, 2000, http://rbm.who.int/docs/abuja-sumrep.htm (accessed 22 April 2009).
15. Abuja Declaration and the Plan of Action, "The African Summit on Roll Back Malaria," 25 April 2000, http://www.rollbackmalaria.org/docs/ abuja-declaration-final.htm (accessed 16 April 2009).
16. ReliefWeb, "Malaria Fight in Africa Needs Better Donor Coordination and More Financial Help, Says World Bank Chief," Press Release (Washington: World Bank, September 2005);
17. and World Bank, Rolling Back Malaria: The Global Strategy and Booster Program (Washington: World Bank, 2005).
18. A. Jack, "Malaria Drug for the Poor 'a Bad Idea'," Financial Times, 2 April 2007;
19. and "Money v Mosquito," Economist 385, no. 8553 (2007): 90.
20. U. Samarasekera, "Drug Subsidy Could Help Tanzania Tackle Malaria," Lancet 371, no. 9622 (2008): 1403-1406.
21. William J. Clinton Foundation, Tanzania Pilot ACT Subsidy: Report on Findings (New York: Clinton Foundation, 2008).
22. M. Enserink, "Global Health: Malaria Drugs, the Coca-Cola Way," Science 322, no. 5905 (2008): 1174.
23. F. Castro-Leal et al., "Public Social Spending in Africa: Do the Poor Benefit?" World Bank Research Observer 14, no. 1 (1999): 49-72;
24. and World Bank, Making Services Work for Poor People, World Development Report (Washington: World Bank, 2003).
25. See Roll Back Malaria, "Summary of Twelfth RBM Partnership Meeting: Decision Points and Next Steps," http://www.rollbackmalaria.org/ partnership/board/meetings/docs/12pbmDecisions.pdf (accessed 16 April 2009).
26. W. Steiger, in memo to PSC colleagues (March 2008).
27. B.R. Bloom, H. Gelband, and R. Laxminarayan, "Consultative Forum on AMFm - The Affordable Medicines Facility-Malaria" (Washington: Resources for the Future, 2008).
28. C. Whitty et al., Opportunities and Threats in Targeting Antimalarials for AMFm: The Role of Diagnostics (Washington: RFF, 2008).
29. In 2006 France, Brazil, Chile, Norway, and the United Kingdom decided to create an international drug purchase facility called UNITAID through a tax on air travel in some countries. The revenue generated from the tax is a truly additional, new source of funds for global public health.